保健医学研究与实践2025，Vol.22Issue(3)：41-46,6.DOI:10.11986/j.issn.1673-873X.2025.03.07
SOS1、FRS2在乳腺浸润性导管癌组织中的表达及与患者临床病理特征的关系
Expression of SOS1 and FRS2 in breast invasive ductal carcinoma tissues and their relationship with clinicopathological characteristics
摘要
Abstract
Objective To investigate the expression of Son of Sevenless Homolog 1(SOS1)and Fibroblast Growth Factor Receptor Substrate 2(FRS2)in breast invasive ductal carcinoma(IDC)tissues and their correlation with clinicopathological characteristics,providing insights for clinical management.Methods A total of 110 IDC patients admitted to Xuancheng Central Hospital from January 2017 to December 2023 were enrolled.Carcinoma tissues and adjacent normal tissues obtained surgically were designated as the IDC group and control group,respectively.The expression of SOS1 and FRS2 in IDC tis-sues and their associations with clinicopathological characteristics were analyzed.Univariate and multivariate logistic regres-sion identified factors influencing axillary lymph node metastasis(ALNM).Results The IDC group exhibited significantly higher positive expression rates of SOS1 and FRS2 compared to the control group(P<0.05).IDC tissues with advanced clinical stages(Ⅲ-Ⅳ),poor differentiation,or lymphovascular invasion showed significantly higher positive expression rates of SOS1 and FRS2 than those with early stages(Ⅰ-Ⅱ),moderate/high differentiation,or no lymphovascular inva-sion(P<0.05).Multivariate analysis identified poor differentiation,lymphovascular invasion,SOS1 positive expression,and FRS2 positive expression as independent risk factors for ALNM(P<0.05).Conclusion SOS1 and FRS2 were mainly positively expressed in IDC tissues,with expression levels correlating with clinical stage,differentiation grade,and lympho-vascular invasion.Both serve as influence factors for ALNM.关键词
非七激酶子同源物1/成纤维生长因子受体底物2/乳腺浸润性导管癌/病理特征/腋窝淋巴结转移Key words
SOS1/FRS2/Breast invasive ductal carcinoma/Pathological characteristics/Axillary lymph node metastasis分类
医药卫生引用本文复制引用
李杨,李启松,丁聪玲,王庆,周慧慧,王漫秋,杨杰..SOS1、FRS2在乳腺浸润性导管癌组织中的表达及与患者临床病理特征的关系[J].保健医学研究与实践,2025,22(3):41-46,6.基金项目
安徽省自然科学基金资助项目(1808185MH1035). （1808185MH1035）
